Vanda pushes Bysanti MDD trial readout to Q1 2027, a year past guidance
Vanda Pharmaceuticals now says its adjunctive-MDD Phase 3 for Bysanti (milsaperidone) will read out in Q1 2027, a year later than the 2026 window it gave three times before.
Executive Summary
- Vanda has walked its own guidance for this MDD readout back by a full year, from a calendar-2026 window repeated across two prior disclosures to a newly stated first-quarter-2027 target.
- The trial itself shows no sign of operational strain: enrollment target, eligibility criteria, and the single primary endpoint have all held steady since the study opened for recruitment.
- The trial's own registered primary completion date sits nearly two years beyond even the newest guided readout, meaning the near-term timeline rests entirely on the sponsor's disclosure cadence rather than a registry-confirmed milestone.
- No competitor in the current Major Depressive Disorder trial field shares Bysanti's target or mechanism class, so the closest comparators only share the same indication and give no basis for benchmarking the eventual result.
The guidance slip
Vanda told investors in May 2025 and again in October 2025 that results from its Phase 3 adjunctive-MDD study of Bysanti (milsaperidone) were expected in 2026. As of a February 2026 update the company still held to that 2026 window. By its most recent quarterly disclosure, the guided date had moved to Q1 2027, a slip of roughly a year from three consecutive prior statements pointing to calendar-2026. The trial, registered as NCT06830044, carries a March 1, 2028 primary completion date on ClinicalTrials.gov that has not changed since the study's first posting. Vanda+1Vanda Pharmaceuticals Reports First Quarter 2025 Financial ResultsMay 7, 2025Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive DisorderNCT06830044
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
The trial itself
NCT06830044 is a randomized, placebo-controlled Phase 3 study testing milsaperidone as an add-on therapy in adults with MDD who have had an inadequate response to prior antidepressant treatment, confirmed using the Antidepressant Treatment Response Questionnaire. The primary endpoint is change from baseline in the Montgomery-Asberg Depression Rating Scale (MADRS), a standard depression-severity measure, against placebo. The trial targets 500 patients across sites in the United States, Czechia, Poland, and Bulgaria, and moved from Not yet recruiting to Recruiting in May 2025. Enrollment target has not changed since the study opened, and the study has undergone one eligibility-criteria edit and zero changes to its primary endpoint. NCT06830044Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive DisorderNCT06830044
What the trial can establish
A randomized, placebo-controlled design with a single prespecified MADRS primary endpoint is built to produce a decision-grade efficacy read for milsaperidone as an adjunctive MDD therapy once it completes. The design supports a direct efficacy comparison against placebo on a validated depression-severity scale, the kind of result regulators and prescribers use to judge antidepressant augmentation therapies. NCT06830044Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive DisorderNCT06830044
The competitive field
The Major Depressive Disorder trial landscape includes Phase 3 programs from Takeda (vortioxetine, a serotonin transporter agent), Janssen (esketamine, an NMDA-targeting agent, and seltorexant, an orexin-2 antagonist), Axsome Therapeutics (solriamfetol, a norepinephrine transporter agent), and Neurocrine Biosciences (NBI-1065845). None of these programs shares milsaperidone's target or mechanism class; each qualifies only as an indication-level neighbor, not a direct comparator. Milsaperidone has no active or terminated trials of record in Vanda's own portfolio outside this study, and no resolved same-mechanism precedent exists to benchmark the eventual MADRS result against.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.